Study of Safety and Immune Response of the Sm14 Vaccine in Adults of Endemic Regions

Learn more about:
Related Clinical Trial
Retrospective Study of Clinical Practice and Management of Imported Schistosomiasis in France Monitoring Schistosome Hybrids Under Under Praziquantel Pressure Selexipag for the Treatment of Schistosomiasis-Associated Pulmonary Arterial Hypertension Correlating Protection Against Malaria With Serum Profiles Against Plasmodium Falciparum Antigen Repertoires Prevalence of Chronic Kidney Disease (CKD) and Risk Factors in Sub-Saharan Africa S. Japonicum and Pregnancy Outcomes Artemisinin-based Combination Therapy-Intermittent Preventive Treatment (ACT-IPT) Trial Among Schoolchildren in Kassena-Nankana, Ghana Study of Safety and Immune Response of the Sm14 Vaccine in Adults of Endemic Regions L-praziquantel Orodispersible Tablets (L-PZQ ODT) in Schistosoma Infected Children The Effect of Praziquantel Treatment on Schistosoma Mansoni Morbidity and re-Infection Along Lake Victoria, Uganda Praziquantel in Children Under Age 4 Schistosoma Haematobium Infections and Praziquantel Antioxidant Supplements in the Reversal of Schistosomal Peri-portal Fibrosis Single-sex Controlled Human Schistosomiasis Infection: Safety and Dose Finding A Phase Ib Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel)(R) With or Without AP 10-701 for Intestinal Schistosomiasis in Healthy Exposed Adults Single-sex Female Controlled Human Schistosomiasis Mansoni Infection An Open Label Dose Finding Safety and Efficacy in Children and Infants Infected With Schistosomiasis (S.Mansoni) Schistosomiasis Effect on Response to Vaccines, Anaemia and Nutritional Status of Children of Northern Senegal Praziquantel-Pharmacokinetic Study Schistosomiasis in Women of Reproductive Age in Burkina Faso: Implications for Control Iron Supplementation in Schistosomiasis and Soil Transmitted Helminths Control Programmes in Zambia Schistosomiasis in Formal and Non-Formal Schools in Uganda: Implications for Control Programmes Using Community-Based Volunteers to Reach Non-Enrolled School Aged Children Through Community-Directed Treatment of Schistosomiasis in School-Aged Children in Rural Northern Ghana Sm-TSP-2 Schistosomiasis Vaccine in Healthy Ugandan Adults Clinical Trial of Bilhvax,a Vaccine Candidate Against Schistosomiasis A Phase I Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel® With or Without GLA-AF for Intestinal Schistosomiasis in Healthy Adults Treatment of Female Genital Schistosomiasis (FGS) With Praziquantel: A Proof-of-Concept Study Schistosomiasis in Senegal Repeated Doses of Praziquantel in Schistosomiasis Treatment (RePST) Childhood Schistosomiasis: a Novel Strategy Extending the Benefits/Reach of Antihelminthic Treatment Anti-Schistosomiasis Vaccine: Sm14 Phase 2b-Sn in School Children Study to Evaluate the Safety of the Vaccine Prepared sm14 Against Schistosomiasis Arachidonic Acid Treatment Against Schistosomiasis Infection in Children Detection of Schistosomiasis CAA in Travellers After High-risk Water Contact Evaluation of Strategies for Improved Uptake of Preventive Treatment for Intestinal Schistosomiasis Health Benefits of Repeated Treatment in Pediatric Schistosomiasis Seropositivity and Adverse Birth Events in Migrants From Bilharzia-endemic Areas Women and Children as the Focus for Control of Schistosomiasis Infections in the Irrigations Area of Burkina Faso

Brief Title

Study of Safety and Immune Response of the Sm14 Vaccine in Adults of Endemic Regions

Official Title

Safety and Immunogenicity Evaluation of the Vaccine Candidate Sm14 in Combination With the Adjuvant Glucopyranosyl Lipid A (GLA-SE) in Adults Living in Endemic Regions for S. Mansoni and S. Haematobium in Senegal. A Comparative, Randomized, Open-label Trial

Brief Summary

      The clinical trial phase 2a is designed to assess the safety of the active ingredient
      (protein + adjuvant) and secondarily its immunogenicity in healthy male adults from 18 to 49
      years of age with a history of infection with intestinal and urinary schistosomiasis, living
      in the Valley of the Senegal River, a highly endemic area for schistosomiasis. Two arms in
      the study will test different doses of GLA-SE adjuvant (2.5 and 5 μg). This phase IIA in
      adults is considered to be a preliminary step in safety before starting trials in children in
      endemic areas to S. mansoni or S. haematobium, target population of the vaccine.

Detailed Description

      A phase 2a trial, self-contained, open-label, randomized, dose-escalation study in two
      parallel arms receiving three (3) injections at D0, D28, D56; both groups receiving 50 μg
      Sm14 vaccine candidate solution, either combined with 2.5µg GLA-SE for the first group and
      5µg for the second one in adults living in a S. mansoni and S. haematobium endemic area.

      Sm14: recombinant protein produced in yeast following Good Manufacturing Practices (GMP)
      conditions, presented in vials containing 0.55 ml solution Sm14, 0.4 ml solution is diluted
      with 0.4 ml of GLA (Synthetic Glucopyranosyl lipid A) for intramuscular administration.

      Medical examinations are performed at D0 (before injection, 1 hr and 4 hr after), and a
      safety evaluation at 24 hrs and 48 hrs, after each injection.

      Blood analysis: Liver function tests - renal function tests - blood counts, at W-1 before
      inclusion, and then 7 days after each injections and at W13 and W21 during the follow-up.

      Blood samples for immune response analysis at time of each injection, and then W12 and W20.

Study Phase

Phase 2

Study Type


Primary Outcome

Number of Participants with Adverse Events as a Measure of Safety and Tolerability.

Secondary Outcome

 Qualitative and quantitative assessment of the Immunogenicity





Study Arms / Comparison Groups

 Group 1
Description:  Adults with an infectious history of S. haematobium and S. mansoni and pretreated with 1 dose of Praziquantel (3 weeks prior to the first vaccine injection) receiving three (3) intramuscular injections of 50 μg Sm14 with 2.5 μg GLA-SE solution at D0, W4, W8 (D=day; W=week). Three-month follow-up (W12, W20).


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

December 6, 2016

Completion Date

June 2, 2017

Primary Completion Date

April 6, 2017

Eligibility Criteria

        Inclusion Criteria:

          -  Adults, male, 18 to 49 years old (inclusive) at the time of inclusion.

          -  Living in one of selected villages in Saint-Louis Region (Senegal).

          -  Free of obvious/severe health problems except schistosomiasis, as established by
             clinical examination and blood analysis, i.e. hematological exams, liver and renal
             function tests.

          -  Written informed consent to participate obtained

          -  Treated with 40mg/kg Praziquantel (PZQ) before inclusion (W-5 to W-4 before the first
             injection) in case of infection with S. mansoni and S. haematobium

          -  Residence in the area during the period of the study.

        Exclusion Criteria:

          -  Adult who does not respond to one of the inclusion criteria

          -  Current or previous chronic administration (defined as more than 14 days) of
             immunosuppressive drugs or other immuno-modifying drugs.

          -  Known hypersensitivity to any component in the Sm14 vaccine or history of allergic

          -  Knowledge of non-infectious chronic disease

          -  Acute disease at time of enrollment.

          -  Other conditions which in opinion of the PI may potentially represent a danger for the
             patient to be enrolled.

          -  Non residence in the study area or intent to move during the study period




18 Years - 49 Years

Accepts Healthy Volunteers

Accepts Healthy Volunteers


Miriam Tendler, MD, PhD, , 

Location Countries


Location Countries


Administrative Informations



Organization ID


Responsible Party

Principal Investigator

Study Sponsor

Oswaldo Cruz Foundation


 Orygen Biotecnologia SA

Study Sponsor

Miriam Tendler, MD, PhD, Study Chair, Oswaldo Cruz Foundation

Verification Date

January 2017